Lucarini A R, Simonini N, Palmieri L, Salvetti A
Cattedra di Terapia Medica Sistematica, Clinica Medica I-University of Pisa, Italy.
Am J Hypertens. 1988 Jul;1(3 Pt 3):211S-213S. doi: 10.1093/ajh/1.3.211s.
To evaluate the humoral and hemodynamic (both systemic and renal) effects of chronic treatment with celiprolol, six out-patients with mild to moderate uncomplicated essential hypertension received placebo for 1 month and celiprolol (400 mg qid) for 6 months. At the end of placebo and of the first and sixth month of treatment, blood pressure (BP), heart rate (HR), renal plasma flow (RPF), glomerular filtration rate (GFR), plasma renin activity (PRA), aldosterone (ALD) and noradrenaline (NA), urinary enzymes (NAG: N-acetyl-beta glucosaminidase, AAP: alanine aminopeptidase) were measured. Compared to placebo, celiprolol significantly and steadily reduced BP and HR. However, although the systemic hemodynamic effect was constant during the whole period of the study, the reduction of renovascular resistance and of plasma noradrenaline, detectable at the first month of therapy, disappeared at the sixth month. However, PRA, plasma aldosterone, GFR, and urinary enzymes did not change. These findings suggest that the antihypertensive effect of celiprolol is well maintained over the 6-month period; the drug did not exert any adverse effect on the kidney, and chronic celiprolol treatment does not influence renal hemodynamics.
为评估塞利洛尔长期治疗对体液及血流动力学（全身和肾脏）的影响，6例轻至中度无并发症的原发性高血压门诊患者接受了1个月的安慰剂治疗和6个月的塞利洛尔（400mg，每日4次）治疗。在安慰剂治疗结束时以及治疗的第1个月和第6个月末，测量血压（BP）、心率（HR）、肾血浆流量（RPF）、肾小球滤过率（GFR）、血浆肾素活性（PRA）、醛固酮（ALD）和去甲肾上腺素（NA）、尿酶（NAG：N-乙酰-β-葡萄糖苷酶，AAP：丙氨酸氨基肽酶）。与安慰剂相比，塞利洛尔显著且持续降低了血压和心率。然而，尽管在整个研究期间全身血流动力学效应保持恒定，但在治疗第1个月时可检测到的肾血管阻力和血浆去甲肾上腺素的降低在第6个月时消失。然而，PRA、血浆醛固酮、GFR和尿酶并未改变。这些发现表明，塞利洛尔的降压作用在6个月期间得到了很好的维持；该药物对肾脏没有任何不良影响，且塞利洛尔长期治疗不影响肾脏血流动力学。
